Switch theme
Sign up to access all valuation multiples
Genoway SA specializes in genetic designs to serve genetically modified (GM) mice, rat and cell lines for the biopharmaceutical industries and research industries.
1999
105
LTM Revenue $23.7M
LTM EBITDA $3.9M
$30.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genoway has a last 12-month revenue of $23.7M and a last 12-month EBITDA of $3.9M.
In the most recent fiscal year, Genoway achieved revenue of $21.5M and an EBITDA of $6.8M.
Genoway expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genoway valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $18.3M | $21.5M | XXX | XXX | XXX |
| Gross Profit | $6.2M | $9.3M | XXX | XXX | XXX |
| Gross Margin | 34% | 43% | XXX | XXX | XXX |
| EBITDA | $3.7M | $6.8M | XXX | XXX | XXX |
| EBITDA Margin | 20% | 32% | XXX | XXX | XXX |
| Net Profit | -$0.3M | $0.8M | XXX | XXX | XXX |
| Net Margin | -2% | 4% | XXX | XXX | XXX |
| Net Debt | $5.6M | $4.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Genoway's stock price is EUR 3 (or $3).
Genoway has current market cap of EUR 26.4M (or $28.4M), and EV of EUR 28.0M (or $30.0M).
See Genoway trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.0M | $28.4M | XXX | XXX | XXX | XXX | $0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Genoway has market cap of $28.4M and EV of $30.0M.
Genoway's trades at 1.3x LTM EV/Revenue multiple, and 7.7x LTM EBITDA.
Analysts estimate Genoway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genoway and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $30.0M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 4.4x | XXX | XXX | XXX |
| P/E | 16.9x | XXX | XXX | XXX |
| P/E/Growth | -0.2x | XXX | XXX | XXX |
| EV/FCF | 21.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenoway's NTM/LTM revenue growth is 4%
Genoway's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Genoway's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genoway's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genoway and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 82% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 36% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 51% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genoway acquired XXX companies to date.
Last acquisition by Genoway was XXXXXXXX, XXXXX XXXXX XXXXXX . Genoway acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genoway founded? | Genoway was founded in 1999. |
| Where is Genoway headquartered? | Genoway is headquartered in France. |
| How many employees does Genoway have? | As of today, Genoway has 105 employees. |
| Is Genoway publicy listed? | Yes, Genoway is a public company listed on PAR. |
| What is the stock symbol of Genoway? | Genoway trades under ALGEN ticker. |
| When did Genoway go public? | Genoway went public in 2007. |
| Who are competitors of Genoway? | Similar companies to Genoway include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Genoway? | Genoway's current market cap is $28.4M |
| What is the current revenue of Genoway? | Genoway's last 12-month revenue is $23.7M. |
| What is the current EBITDA of Genoway? | Genoway's last 12-month EBITDA is $3.9M. |
| What is the current EV/Revenue multiple of Genoway? | Current revenue multiple of Genoway is 1.3x. |
| What is the current EV/EBITDA multiple of Genoway? | Current EBITDA multiple of Genoway is 7.7x. |
| What is the current revenue growth of Genoway? | Genoway revenue growth between 2023 and 2024 was 18%. |
| Is Genoway profitable? | Yes, Genoway is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
